Cargando…
Real-world effectiveness of osteoporosis treatment in the oldest old
SUMMARY: We studied effectiveness of osteoporosis treatment in women older than 80 years, who often are not included in clinical trials. Treatments were as effective on bone density and fractures as in younger women. INTRODUCTION: To study real-world effectiveness of osteoporosis treatment on BMD an...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer London
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360659/ https://www.ncbi.nlm.nih.gov/pubmed/32232509 http://dx.doi.org/10.1007/s00198-020-05380-6 |
_version_ | 1783559255403528192 |
---|---|
author | Ström, O. Lauppe, R. Ljunggren, Ö. Spångéus, A. Ortsäter, G. O’Kelly, J. Åkesson, K. |
author_facet | Ström, O. Lauppe, R. Ljunggren, Ö. Spångéus, A. Ortsäter, G. O’Kelly, J. Åkesson, K. |
author_sort | Ström, O. |
collection | PubMed |
description | SUMMARY: We studied effectiveness of osteoporosis treatment in women older than 80 years, who often are not included in clinical trials. Treatments were as effective on bone density and fractures as in younger women. INTRODUCTION: To study real-world effectiveness of osteoporosis treatment on BMD and fractures in the oldest old women (≥ 80 years) compared with women (60–79 years) in the clinical setting using Swedish health register data. METHODS: National registers and data from DXA machines were used to study effectiveness of all available osteoporosis treatments in women 60–79 and ≥ 80 years using three approaches: (1) Total Hip BMD change up to 8 years after treatment start; (2) fracture incidence where patients served as their own controls, comparing the first 3 months after treatment start with the subsequent 12 months; and (3) comparison of fracture incidence post-fracture in women ≥ 80 years treated with osteoporosis treatment or calcium/vitamin D. RESULTS: Analysis 1: Total Hip BMD increased by up to 6.7% and 7.7% in women 60–79 and ≥ 80 years old, respectively. The mean increase in BMD was 1.1%-units per year in both age groups. Analysis 2: Relative to the 3-month baseline, fracture incidence decreased during the subsequent 12 months of treatment. Incidence rate ratios were estimated at 0.65, 0.74, 0.29, and 0.81 for any, hip, vertebral, and non-hip-non-vertebral fracture, respectively. Analysis 3: A 24-month incidence of any fracture in women ≥ 80 years given post-fracture osteoporosis treatment was lower (HR = 0.78) than in women given calcium/vitamin D, but treatment allocation was not random, with lower mortality (HR = 0.51) in patients receiving OP treatment. CONCLUSIONS: Osteoporosis medication in women > 80 years in clinical practice likely works, and the magnitude of effect is similar to what was estimated in younger women. The choice between osteoporosis treatment and calcium/vitamin D after fracture in women ≥ 80 years is not random but appears associated with the patient’s health status and presence of vertebral fractures, rather than the known risk profile of sustaining a fracture at a high age. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00198-020-05380-6) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-7360659 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer London |
record_format | MEDLINE/PubMed |
spelling | pubmed-73606592020-07-16 Real-world effectiveness of osteoporosis treatment in the oldest old Ström, O. Lauppe, R. Ljunggren, Ö. Spångéus, A. Ortsäter, G. O’Kelly, J. Åkesson, K. Osteoporos Int Original Article SUMMARY: We studied effectiveness of osteoporosis treatment in women older than 80 years, who often are not included in clinical trials. Treatments were as effective on bone density and fractures as in younger women. INTRODUCTION: To study real-world effectiveness of osteoporosis treatment on BMD and fractures in the oldest old women (≥ 80 years) compared with women (60–79 years) in the clinical setting using Swedish health register data. METHODS: National registers and data from DXA machines were used to study effectiveness of all available osteoporosis treatments in women 60–79 and ≥ 80 years using three approaches: (1) Total Hip BMD change up to 8 years after treatment start; (2) fracture incidence where patients served as their own controls, comparing the first 3 months after treatment start with the subsequent 12 months; and (3) comparison of fracture incidence post-fracture in women ≥ 80 years treated with osteoporosis treatment or calcium/vitamin D. RESULTS: Analysis 1: Total Hip BMD increased by up to 6.7% and 7.7% in women 60–79 and ≥ 80 years old, respectively. The mean increase in BMD was 1.1%-units per year in both age groups. Analysis 2: Relative to the 3-month baseline, fracture incidence decreased during the subsequent 12 months of treatment. Incidence rate ratios were estimated at 0.65, 0.74, 0.29, and 0.81 for any, hip, vertebral, and non-hip-non-vertebral fracture, respectively. Analysis 3: A 24-month incidence of any fracture in women ≥ 80 years given post-fracture osteoporosis treatment was lower (HR = 0.78) than in women given calcium/vitamin D, but treatment allocation was not random, with lower mortality (HR = 0.51) in patients receiving OP treatment. CONCLUSIONS: Osteoporosis medication in women > 80 years in clinical practice likely works, and the magnitude of effect is similar to what was estimated in younger women. The choice between osteoporosis treatment and calcium/vitamin D after fracture in women ≥ 80 years is not random but appears associated with the patient’s health status and presence of vertebral fractures, rather than the known risk profile of sustaining a fracture at a high age. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00198-020-05380-6) contains supplementary material, which is available to authorized users. Springer London 2020-03-30 2020 /pmc/articles/PMC7360659/ /pubmed/32232509 http://dx.doi.org/10.1007/s00198-020-05380-6 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Original Article Ström, O. Lauppe, R. Ljunggren, Ö. Spångéus, A. Ortsäter, G. O’Kelly, J. Åkesson, K. Real-world effectiveness of osteoporosis treatment in the oldest old |
title | Real-world effectiveness of osteoporosis treatment in the oldest old |
title_full | Real-world effectiveness of osteoporosis treatment in the oldest old |
title_fullStr | Real-world effectiveness of osteoporosis treatment in the oldest old |
title_full_unstemmed | Real-world effectiveness of osteoporosis treatment in the oldest old |
title_short | Real-world effectiveness of osteoporosis treatment in the oldest old |
title_sort | real-world effectiveness of osteoporosis treatment in the oldest old |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360659/ https://www.ncbi.nlm.nih.gov/pubmed/32232509 http://dx.doi.org/10.1007/s00198-020-05380-6 |
work_keys_str_mv | AT stromo realworldeffectivenessofosteoporosistreatmentintheoldestold AT laupper realworldeffectivenessofosteoporosistreatmentintheoldestold AT ljunggreno realworldeffectivenessofosteoporosistreatmentintheoldestold AT spangeusa realworldeffectivenessofosteoporosistreatmentintheoldestold AT ortsaterg realworldeffectivenessofosteoporosistreatmentintheoldestold AT okellyj realworldeffectivenessofosteoporosistreatmentintheoldestold AT akessonk realworldeffectivenessofosteoporosistreatmentintheoldestold |